Navigation Links
Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema
Date:12/17/2007

Sarasota FL., December 17, 2007 Researchers at Sarasota Memorial Health Care System today announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new, minimally-invasive option for those suffering with advanced widespread emphysema. The study focuses on a procedure called airway bypass that involves creating pathways in the lung for trapped air to escape and in turn, relieve emphysema symptoms including shortness of breath.

Emphysema is a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue. The loss of the lungs' natural elasticity and the collapse of airways in the lung combine to make exhalation ineffective, leaving the emphysema sufferer with hyperinflation because they cant get air out of their lungs. With hyperinflation, breathing becomes inefficient and the patient is always short of breath. Even the most nominal physical activities become difficult for emphysema patients and many become dependent on oxygen therapy.

We are excited to be part of this study because currently treatment options for the emphysema patients are very limited and many patients have a very poor quality of life, states Kirk Voelker, MD, principal investigator of the study at Sarasota Memorial Hospital. By creating new pathways for airflow with the airway bypass procedure, we hope to reduce hyperinflation and improve lung function. If patients can breathe easier it is likely to improve their quality of life.

During airway bypass, physicians will use a flexible bronchoscope to go through the mouth into the airways. There the physician will create new small pathways and place an Exhale Drug-Eluting Stent manufactured by Broncus Technologies, Inc. - to allow the trapped air in the lung to escape. Patients could see an immediate improvement in dyspnea (shortness of breath).

The airway bypass procedure could be an excellent option for those who may be considering lung transplant or who may not be suitable candidates for lung transplant surgery, which is one of the only other treatment options available for patients with this type of emphysema, states Todd Horiuchi, MD and sub-investigator of the study at Sarasota Memorial Hospital.

Physicians commonly use bronchoscopes to examine the airways within the lungs. During the airway bypass procedure physicians will first use a Doppler probe inserted through the bronchoscope to identify a site in the airway that is away from blood vessels. A special needle is then used to make a small opening and an Exhale Drug-Eluting Stent is placed in the passageway to keep it open. The procedure involves placing up to six drug-eluting stents. The total time of the procedure is approximately one to two hours.

This procedure is still under clinical investigation, but early data suggest it may hold promise for patients with emphysema.

Emphysema affects an estimated 60 million people worldwide with more than 3 million sufferers in the United States. There is no cure for emphysema.


'/>"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Broncus Technologies  
Source:Eurekalert

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... Irvine, ca (PRWEB) , ... October 12, 2017 ... ... for the Surgical Wound Market with the addition of its newest module, US ... the $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology: